HF 1904 Summary

• Prohibits removal of HIV/AIDS treatment and prevention drugs from the drug formulary and prior authorization requirements, regardless of other statutory provisions.

• Requires the commissioner to provide the Formulary Committee with impact information on patient care and program costs before implementing prior authorization for any drug, followed by a public forum with 15-day comment period and 15-day notice before implementation.

• Prohibits deletion or modification of preferred drug list drugs based solely on economic or fiscal reasons; requires consultation with the health commissioner, public hearings with adequate notice, and consideration of impacts on public health policies and health disparities.

• Automatically grants prior authorization for 60 days for brand-name mental illness drugs when generic equivalents become available, if the brand drug was part of the recipient's treatment regimen.

• Requires the commissioner of human services to submit a proposed reorganization of the Formulary Committee to legislative health committees by March 1, 2022, including consumer and healthcare professional membership and procedures ensuring public input.